Orphazyme A/S
CSE:ORPHA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Northstar Clean Technologies Inc
XTSX:ROOF
|
CA |
|
S
|
Shanghai Beite Technology Co Ltd
SSE:603009
|
CN |
|
Roblon A/S
CSE:RBLN B
|
DK |
|
Duroc AB
STO:DURC B
|
SE |
|
Walmart Inc
NASDAQ:WMT
|
US |
|
D
|
Daaz Bara Lestari Tbk PT
IDX:DAAZ
|
ID |
|
Leshan Electric Power Co Ltd
SSE:600644
|
CN |
Orphazyme A/S
Research & Development
Orphazyme A/S
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Orphazyme A/S
CSE:ORPHA
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Research & Development
-kr1.5B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-37%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Research & Development
-kr1.6B
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-23%
|
|
|
Galecto Inc
NASDAQ:GLTO
|
Research & Development
-$6.4m
|
CAGR 3-Years
45%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Research & Development
-€292.3m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-22%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Research & Development
-kr774m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-8%
|
|
Orphazyme A/S
Glance View
Orphazyme A/S is a biopharmaceutical company, which engages in the development of treatment for patients living with life-threatening and debilitating rare diseases. The company develops new therapies for the treatment of a family of genetic disorders. The firm's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The firm collaborates with academic institutions in Europe and the United States.
